Autologous Anti-LGR5 CAR-T Cells CNA3103
A preparation of autologous T-lymphocytes transduced to express a chimeric antigen receptor (CAR) targeting the cancer stem cell (CSC) marker leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-LGR5 CAR-T cells CNA3103 selectively target, binds to and lyse LGR5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival, tumor initiation, growth, and metastasis. Its expression is linked to poor survival and poor patient response to therapy. CNA3103 contains the antigen-biding domain of the humanized monoclonal LGR5 antibody BNC101.
| Synonym: | leucine-rich repeat-containing G protein-coupled receptor 5-targeted autologous CAR T cells CNA3103 leucine-rich repeat-containing G protein-coupled receptor 5-targeted autologous CAR T cells CNA3103 Leucine-rich Repeat-containing G Protein-coupled Receptor 5-targeted Autologous CAR T-cells CNA3103 LGR5-targeted autologous CAR-T cells CNA3103 |
|---|---|
| Code name: | CAN 3103 CAN-3103 CAN3103 CNA 3103 CNA-3103 CNA3103 |